MARKET

RARE

RARE

Ultragenyx Pharm
NASDAQ
36.54
+0.09
+0.25%
After Hours: 36.00 -0.54 -1.48% 19:43 12/04 EST
OPEN
36.46
PREV CLOSE
36.45
HIGH
37.25
LOW
36.08
VOLUME
1.24M
TURNOVER
--
52 WEEK HIGH
50.00
52 WEEK LOW
25.81
MARKET CAP
3.53B
P/E (TTM)
-6.1533
1D
5D
1M
3M
1Y
5Y
1D
Ultragenyx Pharmaceutical (RARE) Receives a Buy from Citi
TipRanks · 15h ago
Weekly Report: what happened at RARE last week (1124-1128)?
Weekly Report · 3d ago
Ultragenyx Pharmaceutical (RARE): Evaluating Valuation After Analyst Commentary on Setrusumab Progress and Growth Outlook
Simply Wall St · 5d ago
Ultragenyx Pharmaceutical Breaks Above 200-Day Moving Average - Bullish for RARE
NASDAQ · 6d ago
Ultragenyx Pharmaceutical to Participate in Upcoming Investor Conferences
Reuters · 11/24 21:30
Ultragenyx to Participate in Investor Conferences in December
Barchart · 11/24 15:30
Ultragenyx Pharma Price Target Cut to $50.00/Share From $81.00 by Barclays
Dow Jones · 11/24 14:51
Ultragenyx Pharma Is Maintained at Overweight by Barclays
Dow Jones · 11/24 14:51
More
About RARE
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultrarare genetic diseases. Its therapies and clinical-stage pipeline consist of four product categories: biologics, small molecules, AAV gene therapy, and nucleic acid product candidates. Its four approved product candidates include Crysvita (burosumab) for the treatment of X-linked hypophosphatemia (XLH), and tumor-induced osteomalacia (TIO), Mepsevii (vestronidase alfa) for the treatment of mucopolysaccharidosis VII (MPSVII) or Sly Syndrome, Dojolvi (triheptanoin) for the treatment of long-chain fatty acid oxidation disorders (LC-FAOD), and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia (HoFH). Its clinical product candidates include DTX401, DTX301, UX701, UX143, UX111, and GTX-102. UX143 for the treatment of Osteogenesis Imperfecta.

Webull offers Ultragenyx Pharmaceutical Inc stock information, including NASDAQ: RARE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RARE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RARE stock methods without spending real money on the virtual paper trading platform.